mani
viral
pathogen
encod
motor
protein
name
rna
helicas
display
variou
function
genom
replic
gener
strategi
design
specif
select
drug
target
helicas
treatment
viral
infect
could
act
via
one
follow
mechan
inhibit
ntpase
activ
interfer
atp
bind
therefor
limit
energi
requir
unwind
transloc
alloster
mechan
therefor
stabil
conform
enzym
low
helicas
activ
state
inhibit
nucleic
acid
bind
helicas
inhibit
coupl
atp
hydrolysi
unwind
inhibit
unwind
steric
block
helicas
transloc
recent
vitro
screen
studi
report
sever
benzotriazol
imidazol
imidazodiazepin
phenothiazin
quinolin
anthracyclin
triphenylmethan
tropolon
pyrrol
acridon
small
peptid
bananin
deriv
endow
helicas
inhibit
pathogen
virus
belong
flavivirida
coronavirida
picornavirida
famili
convert
close
doublestrand
dna
rna
helix
two
open
singl
strand
protein
machineri
manipul
polynucleotid
cell
requir
helicas
motor
protein
use
energi
deriv
atp
hydrolysi
sever
dna
rna
helicas
isol
kingdom
life
viru
man
detail
structur
inform
biolog
mechan
clear
outlook
inhibitor
therapeut
relev
antivir
agent
recent
provid
xi
et
al
kwong
et
al
overal
frick
et
al
sever
ssrna
posit
sens
singlestrand
rna
helicas
studi
detail
includ
dengu
fever
viru
dfv
west
nile
viru
wnv
japanes
enceph
viru
jev
gener
recent
articl
antiflavivirida
chemotherapi
publish
ghosh
basu
expand
origin
inform
regard
role
helicas
flavivirida
previous
report
borowski
enzym
promis
target
develop
new
therapi
prevent
agent
sinc
ssrna
virus
belong
famili
like
flavivirida
coronavirida
picornavirida
caus
clinic
signific
diseas
human
anim
determin
life
lost
econom
loss
higher
product
cost
exampl
bovin
viral
diarrhea
viru
bvdv
seriou
welfar
problem
significantli
damag
farm
busi
hepat
c
viru
hcv
global
public
health
issu
major
caus
human
hepat
actual
except
yfv
vaccin
exist
variou
flavivirida
member
therefor
new
therapi
prevent
agent
strongli
need
virus
belong
picornavirida
famili
caus
varieti
ill
includ
mening
cold
heart
infect
conjunct
hepat
famili
includ
nine
genera
compris
major
human
pathogen
name
enteroviru
includ
polioviru
coxsackieviru
echoviru
rhinoviru
approxim
serotyp
hepatoviru
hepat
viru
present
specif
antivir
therapi
avail
treatment
picornavirida
infect
final
sever
acut
respiratori
syndrom
coronaviru
sarscov
envelop
viru
recent
infect
thousand
human
death
vaccin
specif
antivir
therapi
known
viru
retrovirus
ssrna
virus
report
encod
synthesi
helicas
might
simpli
util
helicas
encod
host
cell
instead
protein
recent
shown
hiv
replic
requir
human
deadbox
rna
helicas
ssrna
virus
rna
helicas
implic
sever
function
includ
rna
genom
replic
ribosom
biogenesi
messeng
rna
transcript
premrna
splice
rna
matur
rna
export
degrad
well
rna
translat
base
certain
signatur
motif
amino
acid
sequenc
gorbalenya
koonin
shown
helicas
classifi
sever
genet
famili
two
helicas
famili
group
one
three
larger
superfamili
design
superfamili
superfamili
superfamili
remain
famili
one
similar
dnab
helicas
ecoli
resembl
ecoli
rho
helicas
use
transcript
termin
dnablik
famili
sometim
call
famili
superfamili
contain
viral
protein
helicas
bind
ntp
use
two
structur
common
amino
acid
sequenc
name
motif
motif
ii
describ
walker
et
al
subramanya
et
al
motif
also
known
walker
motifbox
phosphatebind
ploop
also
interact
ribos
motif
ii
also
known
walker
bbox
b
mg
cofactor
bind
loop
atpbind
site
helicas
complet
arginin
finger
catalyt
base
accept
proton
attack
water
molecul
relat
protein
catalyt
base
demonstr
conserv
glutam
near
walker
b
motif
arginin
amino
acid
often
interact
beta
gamma
phosphat
bound
atp
stabil
transit
state
figur
helicas
also
classifi
accord
movement
rel
nucleic
acid
strand
primarili
associ
quaternari
structur
thu
helicas
classifi
base
three
scheme
exampl
helicas
encod
hcv
hepat
c
viru
nonr
rna
helicas
human
papillomaviru
helicas
ring
dna
helicas
function
import
helicas
mean
inhibitor
modul
enzym
potenti
import
therapeut
agent
past
decad
signific
progress
made
develop
highli
select
inhibitor
antivir
anticanc
drug
clinic
use
develop
nontox
helicas
inhibitor
antivir
drug
consider
difficult
develop
drug
design
inhibit
viral
enzym
fact
contrast
proteas
polymeras
helicasesdepend
reaction
still
fulli
elucid
furthermor
helicas
atpbind
site
conserv
class
helicas
also
protein
necessari
cellular
lifecycl
small
gtpase
kinas
aaa
famili
atpas
associ
variou
cellular
activ
even
mitochondri
atp
synthas
atpas
thu
compound
inhibit
helicas
via
atpbind
site
could
toxic
effect
host
cell
mani
viral
pathogen
encod
rna
helicas
demonstr
essenti
viral
replic
pathogenesi
ii
virus
stabl
spread
worldwid
hcv
hepat
c
viru
iii
virus
larg
spread
gener
seriou
health
problem
lack
limit
avail
effect
drug
cvb
human
coxsacki
b
viru
gener
strategi
design
specif
select
drug
treatment
viral
infect
target
helicas
could
act
via
one
follow
mechan
inhibit
ntpase
activ
interfer
atp
bind
therefor
limit
energi
requir
unwind
transloc
inhibit
ntpase
activ
alloster
mechan
therefor
stabil
conform
enzym
low
helicas
activ
state
inhibit
unwind
steric
block
helicas
transloc
develop
small
molecul
antagonist
essenti
proteinprotein
interact
involv
helicas
characterist
helicas
famili
pathogen
virus
belong
flavivirida
coronavirida
picornavirida
famili
report
tabl
flavivirida
larg
famili
relat
positivestrand
rna
virus
current
consist
three
genera
flaviviru
pestiviru
latin
pesti
plagu
hepaciviru
greek
hepato
liver
addit
famili
includ
two
group
virus
gbva
gbvc
current
unassign
specif
genu
await
formal
classif
within
famili
compris
virus
caus
signific
diseas
human
anim
popul
flaviviru
genu
dengu
viru
denv
associ
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
dss
japanes
enceph
viru
jev
west
nile
viru
wnv
yellow
fever
viru
yfv
tickborn
enceph
viru
tbev
pestivirus
anim
pathogen
major
econom
import
livestock
industri
like
bovin
viral
diarrhea
viru
bvdv
border
diseas
viru
bdv
sheep
classic
swine
fever
viru
csfv
hepaciviru
genu
includ
hepat
c
viru
hcv
import
human
pathogen
hcv
identifi
major
caus
human
hepat
global
infect
world
popul
hepaciviru
spread
primarili
direct
contact
human
blood
henc
major
caus
infect
use
unscreen
blood
transfus
reus
needl
syring
adequ
sterilis
world
health
organ
estim
million
peopl
worldwid
present
infect
viru
infect
becom
persist
case
progress
toward
chronic
liver
diseas
lead
develop
cirrhosi
hepatocellular
carcinoma
liver
failur
pegyl
interferon
combin
ribavirin
use
clinic
hepat
due
hcv
unfortun
therapi
requir
lengthi
period
administr
often
associ
sever
advers
event
furthermor
drug
limit
efficaci
sustain
virolog
respons
rate
genotyp
infect
patient
infect
genotyp
deaecellulos
chromatographi
use
triethylammonium
bicarbon
teab
buffer
nai
aceton
emphas
new
therapi
clearli
need
sinc
treatment
infect
gener
diseas
caus
virus
belong
flavivirida
famili
therapeut
strategi
realli
effect
select
avail
hcv
genotyp
nucleotid
sequenc
differ
much
produc
singl
polyprotein
amino
acid
subsequ
process
viral
host
proteas
four
structur
protein
six
nonstructur
protein
altogeth
matur
protein
summar
figur
structur
protein
protein
core
gener
viral
capsid
envelop
protein
cleav
hostsign
peptidas
six
nonstructur
protein
ns
protein
respons
genom
replic
larg
gener
hcvencod
proteas
hcv
helicas
part
bifunct
protein
carri
three
differ
enzymat
activ
helicas
ntpase
serin
proteas
activ
helicas
essenti
viral
replic
make
one
promis
target
antivir
therapi
known
hcv
helicas
inhibitor
classifi
base
mechan
action
first
four
group
cite
inhibitor
ntpase
activ
interfer
ntp
bind
inhibitor
ntpase
activ
alloster
mechan
inhibitor
coupl
ntp
hydrolysi
unwind
reaction
bind
hydrolysi
atp
suppli
energi
allow
helicas
adopt
variou
nucleotid
ligat
state
alloster
caus
conform
chang
nucleic
acid
bind
site
drive
movement
helicas
along
length
nucleic
acid
chain
competit
ntpase
inhibitor
may
lead
decreas
atpas
activ
therefor
reduct
unwind
rate
consequ
non
slowli
hydrolys
atpanalog
seem
effect
tool
inhibit
helicas
activ
like
use
determin
low
level
unwind
hcv
dsrna
howev
ribavirin
triphosph
rtp
inhibit
hcv
ntpasehelicas
competit
mechan
regard
atp
ribavirin
diphosph
rdp
report
figur
even
show
ic
valu
micromolar
rang
demonstr
determin
weakli
enzymat
inhibit
behavior
put
evid
paclitaxel
compound
structur
nonrel
ntp
deriv
abl
block
ntpbind
site
ic
inhibit
atpas
activ
ic
competit
way
abl
inhibit
helicas
activ
concentr
lower
mm
partial
unwind
activ
mediat
competit
ntpase
inhibitor
common
member
class
concentr
need
helicas
inhibit
usual
exceed
ic
valu
time
concentr
ntpase
activ
reach
control
basi
phenomenon
remain
unclear
hand
potent
benzotriazol
helicas
inhibitor
identifi
cours
random
screen
studi
particular
tbbt
known
potent
highli
select
inhibitor
protein
kinas
benzotriazol
drbt
display
ic
valu
respect
figur
contrari
correspond
imidazol
deriv
drbt
benzimidazol
drbi
ntpasehelicas
larg
number
member
flavivirida
famili
hcv
wnv
denv
jev
result
complet
inact
explain
find
bretner
et
al
synthes
studi
new
seri
substitut
alkyl
hydroxi
alkyl
chloro
alkyl
ribofuranos
deriv
shown
figur
tbbt
less
drbt
result
effect
hcv
subgenom
replicon
system
compar
way
inhibit
report
enzymat
essay
show
properti
detect
hand
group
hcv
inhibitor
report
start
compound
contrari
whole
halogen
bromin
atom
afford
cite
caus
either
effect
inhibit
hcv
helicas
determin
dna
substrat
rna
substrat
respect
case
jev
enzym
ic
correspond
bromin
afford
deriv
result
less
effect
time
potent
parent
hcv
helicas
benzotriazol
screen
effect
hcvhelicas
activ
use
dna
substrat
deriv
result
significantli
potent
inhibitor
enzym
respect
analogu
hand
enhanc
activ
observ
aliphat
chain
elong
benzotriazol
benzimidazol
respect
analogu
case
benzimidazol
deriv
howev
inhibitori
activ
low
rang
furthermor
hcv
helicas
activ
alkyl
benzimidazol
test
use
rna
substrat
well
use
viral
ntpasehelicas
display
inhibitori
activ
behaviour
suggest
inhibitor
act
block
ntp
bind
site
enzym
occup
alloster
nucleosid
bind
site
consid
previous
suggest
porter
furthermor
studi
author
observ
replac
alkyl
sidechain
substitu
endow
higher
hydrophil
hydroxyethyl
deriv
figur
higher
hydrophob
chloroethyl
deriv
figur
dramat
decreas
activ
tetrabromobenzotriazol
consequ
seem
small
hydrophob
alkyl
moieti
methyl
ethyl
posit
tetrabromobenzotriazol
could
play
crucial
role
inhibit
hcv
ntpasehelicas
introduct
ribofuranosyl
ring
benzotriazol
tetrabromobenzotriazol
improv
water
solubl
lead
decreas
inhibitori
activ
hcv
enzym
test
substitu
posit
drbt
report
effect
inhibit
hcv
wnv
helicas
ic
respect
ineffect
jev
helicas
contrari
replac
chlorin
atom
benzotriazol
ring
either
bromin
atom
methyl
group
compound
figur
show
lower
activ
compar
drbt
extens
studi
addit
class
nucleosid
analogu
known
ringexpand
nucleosid
ren
fat
involv
ring
report
activ
helicas
unwind
reaction
number
ren
compound
figur
display
ic
valu
micromolar
rang
view
observ
tight
complex
nucleosid
rna
andor
dna
substrat
helicas
mechan
ren
action
might
involv
bind
minor
major
groov
helic
nucleic
acid
substrat
fat
nucleosid
tbbt
nogalamycin
see
compound
recent
use
construct
pharmacophor
model
design
new
japanes
enceph
viru
helicasentpas
inhibitor
use
refin
structur
enzym
hand
ren
triphosph
compound
figur
influenc
unwind
reaction
exert
inhibitori
effect
ic
respect
atpas
activ
enzym
report
figur
compound
contain
heterocycl
system
imidazo
nucleosid
turn
synthes
ribosyl
respect
heterocycl
therefor
explor
potenti
antiflavivirida
activ
ring
system
contain
author
focus
differ
substitu
alkyl
arylalkyl
aromat
group
posit
along
variat
sugar
moieti
posit
ribos
deoxyribos
acycl
deriv
well
attach
base
configur
gener
method
synthesi
design
nucleosid
involv
report
figur
ribosyl
dimethyl
follow
condens
result
imidazol
nucleosid
appropri
substitut
guanidin
deriv
modul
effect
exert
ren
result
inhibit
activ
first
case
mechan
may
involv
interact
ren
dna
rna
substrat
bind
major
minor
groov
doublehelix
case
activ
mechan
may
involv
alloster
bind
site
occupi
nucleosidenucleotidetyp
molecul
includ
limit
ren
occup
alloster
site
enzym
depend
upon
high
level
atp
ntp
concentr
reaction
mixtur
ren
obtain
procedur
screen
inhibit
ntpasehelicas
wnv
one
figur
produc
promis
antivir
effect
ec
concentr
atp
hydrolysi
stimul
suggest
inhibitor
somehow
uncoupl
atpas
helicas
function
regard
ren
may
repres
start
point
develop
highli
select
inhibitor
wnv
ntpasehelicas
recent
start
point
repres
triphenylmethan
deriv
report
chen
et
al
compound
figur
triphenylmethan
moieti
link
propan
identifi
good
inhibitor
suppress
hcv
rna
replic
hcv
replicon
cell
inhibit
atp
hydrolysi
rna
substrat
bind
partial
inhibit
mediat
competit
ntpase
inhibitor
may
avoid
util
compound
chemic
unrel
ntp
reduc
access
ntpbind
site
noncompetit
manner
exampl
calmodulin
antagonist
trifluoperazin
figur
although
molecul
known
interact
domain
hcv
helicas
uncertain
inhibit
result
conform
chang
blockag
atpbind
site
even
tropolon
screen
inhibitor
hcv
helicasecatalyz
dna
unwind
recent
bernatowicz
et
al
describ
sever
deriv
bear
side
chain
connect
sevenmemb
ring
system
nheterocycl
activ
compound
methyl
tropolon
inhibit
rna
replic
ec
show
ic
cc
si
wherea
effici
methyl
tropolon
ec
unfortun
exhibit
lower
si
deriv
cc
tropolon
deriv
report
figur
first
antihelicas
compound
inhibit
hcv
replic
abil
caus
appear
resist
mutant
suggest
inhibit
replic
result
inhibit
enzym
activ
also
inhibit
replic
hcv
subgenom
replicon
cell
cultur
sever
polynucleotid
display
inhibitori
hcv
helicas
activ
inhibit
believ
result
competit
polynucleotid
dna
rna
substrat
effect
could
mimick
synthet
macromolecul
aim
discov
new
antihcv
agent
viropharma
synthes
sever
benzimidazol
deriv
two
compound
figur
show
high
activ
hcv
helicas
although
exact
mechan
still
clear
might
compet
nucleic
acid
manner
mention
particular
benzen
ring
nh
group
could
interact
hydrophob
interact
hydrogen
bound
respect
attempt
extend
sar
analysi
new
dimer
contain
benzimidazol
benzoxazol
pyridinoxazol
benzothiazol
ring
attach
symmetr
linker
synthes
phoon
et
al
summar
figur
preliminari
studi
compound
show
signific
decreas
potenc
benzimidazol
moieti
replac
benzoxazol
benzothiazol
ring
compound
hand
aminobenzimidazolediamid
aminophenyl
benzimidazolediurea
deriv
display
percent
inhibitori
activ
respect
likewis
linker
also
implic
inhibitori
activ
sinc
replac
diamid
linkag
possess
diurea
linkag
compound
led
reduc
potenc
thu
sar
data
indic
benzimidazol
ring
benzen
group
posit
benzimidazol
moieti
natur
linker
essenti
activ
synthesi
analogu
outlin
figur
aminophenol
thiophenol
correspond
pyridin
deriv
react
easili
paminobenzo
acid
presenc
polyphosphor
acid
afford
correspond
oxazol
thiazol
deriv
subsequ
coupl
opportun
acid
dichlorid
furnish
product
belon
et
al
recent
describ
prototyp
symmetr
benzimidazolephenyl
seri
n
n
bi
phenyl
bip
b
deriv
phenyl
figur
bind
directli
hcv
helicas
bind
site
rna
competit
manner
furthermor
report
interact
encod
non
variou
hcv
genotyp
even
dengu
viru
dv
japanes
enceph
viru
jev
even
less
tightli
relat
human
helicas
also
small
peptid
specif
inhibit
hcv
helicas
even
cell
bear
hcv
replicon
peptid
express
bacteria
compos
amino
acid
rrgrtgrgrrgiyr
demonstr
best
enzym
inhibitor
aminoacid
sequenc
ic
surround
put
hcv
helicas
arginin
finger
inhibit
replic
hcv
replicon
cell
ec
reduc
dna
unwind
ic
new
select
inhibitor
hcv
helicas
compound
figur
discov
maga
cowork
show
potent
select
inhibit
ki
studi
inhibit
mechan
reveal
specif
inhibitor
stranddisplac
activ
without
affect
abil
helicas
hydrolys
atp
could
function
competit
inhibitor
respect
nucleic
acid
substrat
decreas
affin
enzym
substrat
molecular
dock
studi
support
explan
therefor
inhibit
unwind
activ
competit
manner
respect
dna
substrat
make
promis
candid
novel
class
antihcv
drug
recent
new
ration
approach
design
select
inhibitor
hcv
helicas
brought
discoveri
novel
hcv
helicas
inhibitor
potenti
could
compet
nucleic
acid
bind
site
occupi
bind
cler
consequ
de
novo
drug
design
predict
e
methyl
methyl
benzoat
figur
synthes
test
hcv
replicon
system
inhibit
hcv
replicon
ec
show
cc
polynucleotid
chain
dna
rna
intercal
compound
potenti
helicas
inhibitor
increas
energi
requir
duplexintercal
complex
unwind
particular
two
anthracyclin
deriv
doxorubicin
nogalamycin
compound
figur
shown
effect
inhibitor
unwind
reaction
limit
applic
treatment
chronic
viral
infect
high
cytotox
weak
penetr
cell
thu
interc
modul
dna
rna
substrat
consid
possibl
antivir
therapi
less
toxic
select
deriv
must
identifi
previous
seen
antibiot
nogalamycin
interact
alloster
bind
site
recent
use
obtain
structurebas
pharmacophor
model
jev
helicasentpas
aim
find
less
toxic
compound
larg
group
amidinoanthracyclin
decreas
acut
toxic
cardiotox
compar
parent
antibiot
screen
hcv
helicas
studi
emerg
one
potent
select
inhibitor
helicas
activ
describ
literatur
deriv
show
figur
act
via
intercal
doublestrand
dna
substrat
also
imped
format
activ
helicas
complex
via
competit
enzym
access
substrat
test
subgenom
hcv
replicon
system
show
ec
cc
class
compound
probabl
act
via
intercal
doublestrand
nucleic
acid
strong
specif
rna
acridon
deriv
direct
interact
viral
helicas
exclud
larg
group
acridon
test
stankiewiczdrogon
et
al
use
direct
fluorometr
helicas
activ
assay
determin
inhibitori
properti
toward
helicas
hcv
preliminari
studi
n
amid
n
amid
acid
emerg
effici
rna
replic
inhibitor
good
specif
subgenom
replicon
system
low
cytotox
figur
even
thiazolpiperazinyl
acridon
deriv
demonstr
act
potent
agent
hcv
replicon
ec
select
inhibitor
hcv
helicas
albeit
low
potenc
ic
compar
acridon
deriv
see
amid
bond
form
derivat
acid
amin
seem
increas
affin
select
enzym
final
intent
improv
antivir
activ
acridon
stankiewiczdrogon
et
al
prepar
new
class
compound
name
acid
maca
group
compound
figur
came
effici
inhibitor
helicas
vitro
assay
also
potent
inhibitor
hcv
replic
endow
low
cytotox
human
hepatoma
cell
envelop
singlestrand
positivesens
rna
ssrna
viru
sar
coronaviru
sarscov
recent
identifi
etiolog
agent
sever
acut
respiratori
syndrom
sar
human
ten
thousand
case
sar
worldwid
includ
death
report
data
although
initi
global
outbreak
sar
appear
success
contain
remain
seriou
concern
vaccin
effect
drug
treatment
actual
avail
recent
tanner
cowork
found
bananin
three
deriv
figur
function
noncompetit
sarscov
helicas
inhibitor
ic
valu
micromolar
rang
site
differ
atp
nucleic
acid
bind
site
caus
inhibit
probabl
alloster
mechan
foetal
rhesu
infect
sarscov
bananin
inhibit
viral
replic
ic
low
host
cellular
toxic
cc
final
last
year
variou
molecul
detect
show
interest
promis
anticoronavirida
activ
unfortun
mani
identifi
clear
molecular
target
mechan
action
fact
remain
eventu
target
could
helicas
mind
report
briefli
new
class
compound
emerg
recent
publish
work
among
glycopeptid
antibiot
seem
interfer
coronaviru
entri
process
exclud
unknown
cellular
target
pyridin
noxid
deriv
plant
lectin
probabl
interfer
glycan
spike
protein
viru
entri
viru
releas
phenanthroindolizin
phenanthroquinolizidin
tetrahydroquinolin
oxocarbaz
deriv
inhibitor
human
cathepsin
l
entri
blocker
includ
mening
cold
heart
infect
conjunct
hepat
recent
carta
cowork
report
synthesi
antivir
screen
seri
n
yl
phenyl
alkylcarboxamid
n
n
bi
yl
phenyl
alkyldicarboxamid
see
figur
compound
evalu
vitro
cytotox
antivir
activ
wide
spectrum
ssrna
virus
like
bovin
viral
diarrhea
viru
bvdv
yellow
fever
viru
yfv
coxsaki
viru
b
polio
viru
human
immunodefici
viru
inhibit
n
yl
phenyl
alkylcarboxamid
deriv
particular
two
emerg
select
activ
ec
cc
activ
ec
cc
figur
n
yl
phenyl
alkylcarboxamid
g
h
prepar
condens
amino
deriv
appropri
anhydrid
stir
c
h
shown
figur
n
n
bi
yl
phenyl
alkyldicarboxamid
g
h
ik
report
figur
condens
amin
benzotriazol
suitabl
diacyl
dichlorid
among
n
n
bi
yl
phenyl
alkyldicarboxamid
exhibit
good
activ
enterovirus
ec
deriv
show
select
activ
ec
result
complet
inact
virus
screen
n
yl
phenyl
alkylcarboxamid
evalu
silico
model
helicas
exemplifi
compound
b
figur
portion
enzym
contain
bind
site
interact
inhibitor
consist
two
loop
part
two
part
three
helic
import
notic
respect
n
yl
phenyl
alkylcarboxamid
seri
n
n
bi
yl
phenyl
alkyldicarboxamid
deriv
bind
helicas
differ
manner
expect
due
differ
shape
dimens
well
quantifi
valu
solvent
access
volum
new
class
inhibitor
averag
almost
doubl
compar
previou
molecular
seri
eg
versu
resp
accordingli
imposs
protein
pocket
host
n
n
bi
yl
phenyl
alkyldicarboxamid
bind
mode
result
form
dock
studi
reveal
one
two
ident
inhibitor
moieti
posit
well
within
bind
pocket
howev
correspond
favor
bind
mode
activ
compound
format
new
small
network
hbond
enzym
observ
particular
analysi
trajectori
md
simul
complex
exampl
indic
constant
presenc
hbond
involv
carbonyl
oxygen
atom
side
chain
triazol
n
atom
drug
character
averag
dynam
length
adl
time
possibl
verifi
format
two
hbond
interact
former
co
backbon
group
nh
group
amid
moieti
adl
latter
carbonyl
oxygen
atom
co
group
amid
moieti
side
chain
hydroxyl
group
adl
compound
also
exhibit
select
coxsacki
unfortun
homolog
standard
techniqu
abl
produc
reliabl
model
viru
helicas
due
low
sequenc
ident
found
align
process
absenc
model
helicas
activ
explain
adopt
align
analysi
put
bind
site
propos
carta
cowork
compos
residu
accord
align
bind
site
differ
residu
among
mutat
follow
analysi
preliminari
visual
inspect
base
swap
ser
arg
polio
helicas
conclud
import
residu
case
compound
featur
chlorin
atom
substitu
fact
posit
charg
side
chain
place
averag
distanc
cl
atom
thu
sensibl
result
strong
electrostat
interact
inhibitor
protein
specul
may
account
part
select
compound
respect
clearli
await
confirm
simul
perform
correspond
protein
model
